34417-79-3

Basic information

• Product Name: 1,4-Benzenediol, 2-bromo-5,6-dimethoxy-3-methyl-
• CAS NO: 34417-79-3
• Molecular Formula: C9H11BrO4
• Molecular Weight: 263.088
• Mol File: 34417-79-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1,4-Benzenediol, 2-bromo-5,6-dimethoxy-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Benzenediol, 2-bromo-5,6-dimethoxy-3-methyl-(34417-79-3)
• EPA Substance Registry System: 1,4-Benzenediol, 2-bromo-5,6-dimethoxy-3-methyl-(34417-79-3)

Safety Data

• Hazardous Substances Data: 34417-79-3(Hazardous Substances Data)

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 9 carbon atoms, 11 hydrogen atoms, 1 bromine atom, and 4 oxygen atoms.

Explanation

Resorcinol is a dihydroxybenzene, which means it has two hydroxyl (OH) groups attached to a benzene ring. The compound in question is a derivative of resorcinol, meaning it has been chemically modified to include additional functional groups.

Explanation

The presence of a bromine atom in the compound provides unique chemical properties and reactivity compared to other halogenated derivatives.

Explanation

Methoxy groups (-OCH3) are added to the benzene ring, which can influence the compound's polarity, reactivity, and solubility.

Explanation

A methyl group (-CH3) is attached to one of the hydroxy groups, which can affect the compound's steric hindrance and reactivity.

Explanation

Organic compounds are primarily composed of carbon and hydrogen atoms, and this compound is no exception.

Explanation

Due to its unique structure and properties, this compound may have potential applications in the development of new drugs or pharmaceuticals.

Explanation

The compound's structure and functional groups make it a candidate for use in various organic synthesis reactions, potentially leading to the creation of new compounds with specific properties.

Explanation

The way the compound is synthesized can influence its specific properties, such as purity, stability, and reactivity, which in turn can affect its potential applications.

Explanation

The compound's reactivity with other compounds and its ability to undergo various chemical reactions can determine its potential uses in different applications.

Derivative of resorcinol

Dihydroxybenzene

Bromine atom

Attached to the benzene ring

Methoxy groups

Two on the benzene ring

Methyl group

Attached to one of the hydroxy groups

Organic compound

Belongs to the class of organic compounds

Pharmaceutical applications

Potential use in the development of pharmaceuticals

Organic synthesis

Potential use in organic synthesis reactions

Synthesis method

Specific properties and potential uses depend on the synthesis method

Reactions

Specific properties and potential uses depend on the reactions it undergoes

Upstream product

• 3066-90-8 2,3-dimethoxy-5-methylbenzene-1,4-diol 
• 30685-17-7 2-bromo-5,6-dimethoxy-3-methylcyclohexane-2,5-diene-1,4-dione 

Downstream Products

• 73875-28-2 6-Bromo-2,3-dimethoxy-5-methylhydroquinone bis<2-methoxyethoxymethyl ether> 
• 34407-31-3 1-bromo-3,4-dimethoxy-2,5-bis(methoxymethoxy)-6-methylbenzene 
• 73875-23-7 2,3-Dimethoxy-5-methyl-6-(3-methyl-4-phenylsulfonyl-2-butenyl)-hydroquinone bis<2-methoxyethoxymethyl ether> 
• 727-81-1 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA

The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

Reduction of Quinones with 2-Propanol over Hydrous Zirconium Oxide

-

Hydroquinone derivatives and preparation thereof

The novel hydroquinone derivatives of the formula (I) are useful intermediates for the preparation of coenzyme Q, vitamin K and the polyprenyltrimethylquinones: STR1 wherein R1 is lower alkyl, lower alkoxy lower alkyl or methoxyethoxymethyl, R2 and R3 are each methyl or methoxy, or R2 and R3, taken together with the carbon atoms from which they depend, define a benzene ring, and R4 is a substituted or unsubstituted aromatic hydrocarbon. The compounds (I) are readily prepared either by reacting a Grignard reagent of the formula (II) with a halosulfone (III) in the presence of a copper compound, or by reacting a copper derivative (II') of the Grignard reagent (II) with a halo-sulfone (III), as follows: STR2 wherein R1, R2, R3 and R4 are defined as above, and X is a halogen atom or a tosyl group.